| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
- Isoviolanthin targets the TGF-β/Smad signaling pathway (key proteins: TGF-βRII, p-Smad2, p-Smad3) and PI3K/Akt/mTOR signaling pathway (key proteins: p-PI3K, p-Akt, p-mTOR)[1]
|
|---|---|
| ln Vitro |
- Reversal of TGF-β1-mediated epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) cells: In HepG2 and Huh7 cells treated with TGF-β1 (5 ng/mL), Isoviolanthin (5, 10, 20 μM) acted in a concentration-dependent manner. At 20 μM, it increased epithelial marker E-cadherin by 2.8-fold (western blot) and 2.5-fold (mRNA, qPCR), while decreasing mesenchymal markers N-cadherin (65% by western blot, 60% by mRNA) and vimentin (62% by western blot, 58% by mRNA) vs. the TGF-β1-only group[1]
- Inhibition of pathway activation: Isoviolanthin (20 μM) reduced phosphorylation of Smad2 (70%), Smad3 (68%), PI3K (65%), Akt (72%), and mTOR (66%) in TGF-β1-stimulated HepG2 cells (western blot); total protein levels of these targets remained unchanged[1] - Suppression of migration and invasion: In Transwell assays, Isoviolanthin (20 μM) reduced migration rate by 68% and invasion rate by 72% in TGF-β1-stimulated HepG2 cells vs. the TGF-β1-only group. In wound-healing assays, it prolonged wound closure time by 2.3-fold at 20 μM[1] - Inhibition of colony formation: Isoviolanthin (20 μM) decreased colony number by 65% in TGF-β1-stimulated HepG2 cells (crystal violet staining); 10 μM caused a 40% reduction, and 5 μM had no significant effect[1] |
| Cell Assay |
- Cell viability assay: HepG2/Huh7 cells (5×10³ cells/well) were treated with Isoviolanthin (0–40 μM) alone or with TGF-β1 (5 ng/mL) for 48 hours. MTT reagent was added, and absorbance was measured at 570 nm; ≤20 μM Isoviolanthin had no effect on HCC cell viability[1]
- Western blot assay: Treated HCC cells were lysed, proteins separated by SDS-PAGE, and blotted with antibodies against EMT markers (E-cadherin, N-cadherin, vimentin) and pathway proteins (p-Smad2, p-Smad3, p-PI3K, p-Akt, p-mTOR); GAPDH was used as internal control[1] - qPCR assay: Total RNA from treated cells was reverse-transcribed to cDNA; qPCR was performed with primers for EMT markers, and relative mRNA was calculated via 2⁻ΔΔCt method[1] - Transwell assay: For migration, treated cells (1×10⁵/well) were seeded in Transwell inserts (no Matrigel); for invasion, inserts were coated with Matrigel (2×10⁵ cells/well). After 24 hours, cells on the lower surface were stained and counted[1] - Colony formation assay: Treated cells (500/well) were incubated for 14 days, fixed, stained with crystal violet, and colonies (>50 cells) were counted[1] |
| References | |
| Additional Infomation |
It has been reported that isovioletin exists in passionflower (Passiflora sexflora) and aster (Angiopteris evecta), and there are related data reports.
- Isovioletin is a natural compound extracted from the stem of Dendrobium officinale (a traditional Chinese medicine plant)[1] - Its anti-epithelial-mesenchymal transition (EMT) effect in hepatocellular carcinoma (HCC) cells is mediated by the inhibition of the TGF-β/Smad and PI3K/Akt/mTOR pathways, which regulate the progression of EMT and HCC[1] |
| Molecular Formula |
C27H30O14
|
|---|---|
| Molecular Weight |
578.518709659576
|
| Exact Mass |
578.164
|
| CAS # |
40788-84-9
|
| PubChem CID |
101422758
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
41
|
| Complexity |
970
|
| Defined Atom Stereocenter Count |
10
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~432.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7285 mL | 8.6427 mL | 17.2855 mL | |
| 5 mM | 0.3457 mL | 1.7285 mL | 3.4571 mL | |
| 10 mM | 0.1729 mL | 0.8643 mL | 1.7285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
